Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Doan Y. Dao has a total of 119 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effectiveness and implementation of decentralized, community- and primary care-based strategies in promoting hepatitis B testing uptake: a systematic review and meta-analysis

    by Thanh Van Kim, Trang Ngoc Doan Pham, Paul Phan, Minh Huu Nhat Le, Quan Le, Phuong Thi Nguyen, Ha Thi Nguyen, Dan Xuan Nguyen, Binh Trang, Chelsea Cao, et al.


  • Open Access

    Expanding Hepatitis B Screening with Point-of-Care Rapid Testing in Primary Care: An Implementation Science Study

    by Trang N. D. Pham, Long B. Hoang, Diem V. B Dao, Thao T. Dang, Van T. Nguyen, Duc H. Le, Thai N. Truong, Toan T. Le, Bao Q. Duong, Tram T. Trinh, et al.

    Background: Vietnam faces a significant burden of hepatitis B virus (HBV) with around 10% of the population living with HBV and up to 80% unaware of their infection status. This study implemented a strategy using point-of-care rapid testing (POC-RT) for early HBV detection and linkage to care in primary care settings. The EPIS frameworks guided implementation, assessing barriers, enablers, feasibility, and acceptability. Method: The implementation plan integrated insights from participating site’s authorities, local policies, practices, and patient pathways. A mixed-methods approach was employed at three primary care clinics in North Vietnam. Each site received 200-300 POC-RT test kits for use within 10 weeks. Patients received pre- and post-screening consultations for HBV using POC-RT, followed by referrals. Quantitative and qualitative data was collected to assess barriers, enablers, feasibility, and acceptability. Results: Out of 600 POC-RT tests, 24 HBV positive cases were identified. Nine cases from public clinics received follow-up testing and specialist referrals within two weeks. Patients favored POC-RT for its simplicity, minimal blood requirement, and no cost. Physicians found POC-RT feasible for mass screenings, but noted challenges related to older adults’ skin thickness and blood volume accuracy. Linkage to care was satisfactory, but patients desired more health information during treatment. Conclusion: Implementing POC-RT at primary care settings with comprehensive consultation and linkage to care is feasible and well-received. Patient feedback underscores the need for ongoing health information during treatment and follow-up, which is vital for retention in care. Enhancing the test kit design could further enhance POC-RT uptake in the population. Research in Context: Evidence before this study: As of May 1, 2024, a comprehensive search on PubMed and Google Scholar using the terms (“HBV” or “viral hepatitis B” or “hepatitis B virus”) AND “point-of-care” AND “screening” AND “Vietnam” revealed no relevant studies specifically investigating the use of lateral capillary blood flow point-of-care rapid tests (POC-RT) for HBV screening in Vietnam. This highlights a significant gap in the literature regarding the implementation of POC-RT for HBV in this region. Added value of this study: This study is pioneering in its application of the Exploration-Preparation-Implementation-Sustainment (EPIS) framework to incorporate POC-RT for HBV screening at the primary care level in Vietnam. It adopts a universal screening approach, recommending HBV screening for all patients irrespective of their risk profiles. This is a paradigm shift in HBV testing strategy in Vietnam. Until now, HBV testing is typically based on clinical signs and symptoms of HBV related end stage liver disease in Vietnam. As a result, only an estimated 20-30% of people living with HBV are diagnosed and thus 1.32% of the eligible are on anti-viral therapies. Our proposed study suggested shifting from a model of HBsAg testing based on clinical indication to a public health model of routine community wide HBsAg testing to achieve greater absolute and more equitable reach of HBV diagnosis across demographic characteristics. Additionally, the study documents how local authorities and healthcare workers have adapted to using POC-RT and the universal screening approach in both public and private primary care facilities at central and provincial levels. Furthermore, it identifies challenges related to test selection and patient linkage to care, while also considering patient perspectives on mass screening feasibility and acceptability. Implications of all the available evidence: Given the high prevalence of HBV and the significant proportion of individuals unaware of their infection status and unscreened for HBV, Vietnam would benefit from a proactive universal screening strategy. Decentralizing screening services using POC-RT at the primary care level is strategically essential toward this universal premise. Future research should focus on broader implementation and dissemination of POC-RT in primary care and other resource-limited settings, with an emphasis on effective methods for ensuring linkage to care. Taken together, this study’s novelty lies in its systematic approach to integrating POC-RT in Vietnam’s healthcare infrastructure, potentially setting a precedent for similar interventions in other regions with high HBV prevalence and limited resources


  • Open Access

    Low HBV knowledge is associated with low HBV vaccination uptake in general adult population despite incentivization of HBV vaccination

    by Thanh Van Kim, Trang Ngoc Doan Pham, Brian Do, Diem Vu Bich Dao, Dan Xuan Nguyen, William Lee, Robert Gish, Gary Mize, Amy Trang, Anh Le, et al.

    Background: Hepatitis B virus (HBV) vaccination in Vietnamese adults remains low and unequally distributed. We conducted a study on HBV-naïve adults living in Ho Chi Minh City, Viet Nam, to determine barriers associated with HBV vaccination uptake after removing the financial barrier by providing free coupons for HBV vaccination. Methods: After being screened for HBsAg, anti-HBs, and anti-HBc, 284 HBV-naïve study participants aged 18 and over (i.e., negative for HBsAg, anti-HBs, and anti-HBc total) were provided free 3-dose HBV vaccine coupons. Next, study participants’ receipt of 1st, 2nd, and 3rd doses of HBV vaccine was documented at a pre-specified study healthcare facility, where HBV vaccines were distributed at no cost to the participants. Upon study entry, participants answered questionnaires on sociodemographics, knowledge of HBV and HBV vaccination, and related social and behavioral factors. The proportions of three doses of HBV vaccine uptake and their confidence intervals were analyzed. Associations of HBV vaccine initiation with exposures at study entry were evaluated using modified Poisson regression. Results: 98.9% (281 of 284) of study participants had complete data and were included in the analysis. The proportion of participants obtaining the 1st, 2nd, and 3rd doses of HBV vaccine was 11.7% (95% Confidence Interval [95% CI] 8.0-15.5%), 10.7% (95%CI 7.1–14.3%), and 8.9% (95%CI 5.6–12.2%), respectively. On the other hand, participants were more likely to initiate the 1st dose if they had adequate knowledge of transmission (adjusted relative risk [aRR] = 2.58, 95% CI 1.12–5.92), adequate knowledge of severity (aRR = 6.75, 95%CI 3.38–13.48), and annual health-checking seeking behavior (aRR = 2.04, 95%CI 1.07–3.87). Conclusion: We documented a low HBV vaccination uptake despite incentivization. However, increased vaccine initiation was associated with better HBV knowledge and annual health check-up adherence. When considering expanding HBV vaccination to the general adult population, we should appreciate that HBV knowledge is an independent predictor of vaccine uptake.


  • Open Access

    Approach to Liver Transplantation: Is There a Difference between East and West?

    by Nazli Begum Ozturk, Nathanial Bartosek, Merih Deniz Toruner, Aymen Mumtaz, Cem Simsek, Doan Dao, Behnam Saberi, Ahmet Gurakar

    Liver transplantation (LT) remains the only curative treatment for end-stage liver disease as well as acute liver failure. With the exponential increase in organ demand due to the increasing incidence and prevalence of liver diseases, the need to overcome the supply and demand mismatch has arisen. In this review, we discuss the current universal status of LT, emphasizing various LT practices worldwide.


  • Open Access

    Low HBV Knowledge is Associated with Low HBV Vaccination Uptake in General Adult Population Despite Incentivization of HBV Vaccination

    by Thanh Van Kim, Trang Nguyen Doan Pham, Brian Do, Diem Vu Bich Dao, Dan Xuan Nguyen, William Lee, Robert Gish, Gary Mize, Amy Trang, Anh Le, et al.

    Background. Hepatitis B virus (HBV) vaccination in Vietnamese adults remains low and unequally distributed. We conducted a study on HBV-naïve adults living in Ho Chi Minh City, Viet Nam, to determine barriers associated with HBV vaccination uptake after removing the financial barrier by providing free coupons for HBV vaccination. Methods. After being screened for HBsAg, anti-HBs, and anti-HBc, 284 HBV-naïve study participants aged 18 and over (i.e., negative for HBsAg, anti-HBs, and anti-HBc total) were distributed with free 3-dose HBV vaccine coupons. Next, study participants’ receipt of 1st, 2nd, and 3rd doses of HBV vaccine was documented at a pre-specified study healthcare facility, where HBV vaccines were distributed at no cost to the participants. Upon study entry, participants answered questionnaires on sociodemographics, knowledge of HBV and HBV vaccination, and related social and behavioral factors. The proportions of three doses of HBV vaccine uptake and their confidence intervals were analyzed. Associations of HBV vaccine initiation with exposures at study entry were evaluated using modified Poisson regression. Results. 98.9% (281 of 284) of study participants had complete data and were included in the analysis. The proportion of obtaining the 1st, 2nd, and 3rd doses of HBV vaccine was 11.7% (95%CI 8.0-15.5%), 10.7% (95%CI 7.1-14.3%), and 8.9% (95%CI 5.6-12.2%), respectively. On the other hand, participants were more likely to initiate the 1st dose if they had adequate knowledge of transmission (adjusted relative risk [aRR] = 2.58, 95% Confidence Interval [95% CI] 1.12-5.92), adequate knowledge of severity (aRR = 6.75, 95%CI 3.38-13.48), and annual health-checking seeking behavior (aRR = 2.04, 95%CI 1.07-3.87). Conclusion. We documented a low HBV vaccination uptake despite incentivization. However, increased vaccine initiation was associated with better HBV knowledge and annual health check-up adherence. When considering expanding HBV vaccination to the general adult population, we should appreciate that HBV knowledge is an independent predictor of vaccine uptake.

  • Open Access

    Surveillance and treatment of primary hepatocellular carcinoma (aka. STOP HCC): protocol for a prospective cohort study of high-risk patients for HCC using GALAD-score

    by Thai Ngoc Truong, Trang Ngoc Doan Pham, Long Bao Hoang, Van Thi Nguyen, Hang Viet Dao, Diem Vu Bich Dao, Saleh Alessy, Hien Ba Pham, Thuy Thi Thu Pham, Linh Duc Duy Nguyen, et al.

    Background: Vietnam and Saudi Arabia have high disease burden of primary hepatocellular carcinoma (HCC). Early detection in asymptomatic patients at risk for HCC is a strategy to improve survival outcomes in HCC management. GALAD score, a serum-based panel, has demonstrated promising clinical utility in HCC management. However, in order to ascertain its potential role in the surveillance of the early detection of HCC, GALAD needs to be validated prospectively for clinical surveillance of HCC (i.e., phase IV biomarker validation study). Thus, we propose to conduct a phase IV biomarker validation study to prospectively survey a cohort of patients with advanced fibrosis or compensated cirrhosis, irrespective of etiologies, using semi-annual abdominal ultrasound and GALAD score for five years. Methods: We plan to recruit a cohort of 1,600 patients, male or female, with advanced fibrosis or cirrhosis (i.e., F3 or F4) and MELD ≤ 15, in Vietnam and Saudi Arabia (n = 800 each). Individuals with a liver mass ≥ 1 cm in diameter, elevated alpha-fetoprotein (AFP) (≥ 9 ng/mL), and/or elevated GALAD score (≥ -0.63) will be scanned with dynamic contrast-enhanced magnetic resonance imaging (MRI), and a diagnosis of HCC will be made by Liver Imaging Reporting and Data System (LiRADS) assessment (LiRADS-5). Additionally, those who do not exhibit abnormal imaging findings, elevated AFP titer, and/or elevated GALAD score will obtain a dynamic contrast-enhanced MRI annually for five years to assess for HCC. Only MRI nearest to the time of GALAD score measurement, ultrasound and/or AFP evaluation will be included in the diagnostic validation analysis. MRI will be replaced with an abdominal computed tomography scan when MRI results are poor due to patient conditions such as movement etc. Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MRI will not be carried out in study sites in both countries. Bootstrap resampling technique will be used to account for repeated measures to estimate standard errors and confidence intervals. Additionally, we will use the Cox proportional hazards regression model with covariates tailored to the hypothesis under investigation for time-to-HCC data as predicted by time-varying biomarker data. Discussion: The present work will evaluate the performance of GALAD score in early detection of liver cancer. Furthermore, by leveraging the prospective cohort, we will establish a biorepository of longitudinally collected biospecimens from patients with advanced fibrosis or cirrhosis to be used as a reference set for future research in early detection of HCC in the two countries. Trial registration: Name of the registry: ClinicalTrials.gov Registration date: 22 April 2022 Trial registration number: NCT05342350 URL of trial registry record


  • Open Access

    Relationship of Hepatocellular Carcinoma Stage and Hepatic Function to Health-Related Quality of Life: A Single Center Analysis

    by Amol Gupta, Jane Zorzi, Won Jin Ho, Marina Baretti, Nilofer Saba Azad, Paige Griffith, Doan Dao, Amy Kim, Benjamin Philosophe, Christos Georgiades, et al.

    Health-related quality of life (HRQoL) is known to be an important prognostic indicator and clinical endpoint for patients with hepatocellular carcinoma (HCC). However, the correlation of the Barcelona Clinic Liver Cancer (BCLC) stage with HRQoL in HCC has not been previously studied. We examined the relationship between BCLC stage, Child–Pugh (CP) score, and Eastern Cooperative Oncology Group (ECOG) performance status on HRQoL for patients who presented at a multidisciplinary liver cancer clinic. HRQoL was assessed using the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire. Fifty-one patients met our inclusion criteria. The FACT-Hep total and subscales showed no significant association with BCLC stages (p = 0.224). Patients with CP B had significantly more impairment in FACT-Hep than patients with CP A. These data indicate that in patients with HCC, impaired liver function is associated with reduced quality of life, whereas the BCLC stage poorly correlates with quality of life metrics. Impairment of quality of life is common in HCC patients and further studies are warranted to determine the impact of early supportive interventions on HRQoL and survival outcomes.


  • Open Access

    Circulating Biomarkers for the Early Diagnosis and Management of Hepatocellular Carcinoma with Potential Application in Resource-Limited Settings

    by Annabelle Pan, Thai N. Truong, Ying-Hsiu Su, Doan Y Dao

    Hepatocellular carcinoma (HCC) is among the world’s third most lethal cancers. In resource-limited settings (RLS), up to 70% of HCCs are diagnosed with limited curative treatments at an advanced symptomatic stage. Even when HCC is detected early and resection surgery is offered, the post-operative recurrence rate after resection exceeds 70% in five years, of which about 50% occur within two years of surgery. There are no specific biomarkers addressing the surveillance of HCC recurrence due to the limited sensitivity of the available methods. The primary goal in the early diagnosis and management of HCC is to cure disease and improve survival, respectively. Circulating biomarkers can be used as screening, diagnostic, prognostic, and predictive biomarkers to achieve the primary goal of HCC. In this review, we highlighted key circulating blood- or urine-based HCC biomarkers and considered their potential applications in resource-limited settings, where the unmet medical needs of HCC are disproportionately highly significant.


  • Significant gaps in hepatitis B vaccination in adults in Viet Nam: Important targets toward hepatitis B elimination by 2030

    by Thanh V. Kim, Trang N.D. Pham, Duc H. Le, Diem V.B. Dao, Loc T.B. Phan, Anh Le, Amy Trang, Hong K. Tang, Jason J. Liu, Doan Y Dao


  • Open Access

    Establishing baseline framework for hepatitis B virus micro-elimination in Ho Chi Minh City, Vietnam – a community-based seroprevalence study

    by Trang N.D. Pham, Duc H. Le, Diem V.B. Dao, Loc T.B. Phan, Thuy T.T. Pham, Toan B. Nguyen, Gary W. Mize, Robert G. Gish, William M. Lee, Amy Trang, et al.